Current Status and Advances in Anti-Androgen Therapy for Triple-Negative Breast Cancer
{{output}}
The heterogeneity of triple-negative breast cancer (TNBC) has spurred the exploration of precision therapies based on molecular subtypes, with the androgen receptor (AR)-positive subtype emerging as a potential therapeutic target. The treatment of AR-positive ... ...
